The Zurcher Kantonalbank Zurich Cantonalbank Cuts Stake in Zoetis Inc (ZTS)

The Zurcher Kantonalbank Zurich Cantonalbank Cuts Stake in Zoetis Inc (ZTS)

A number of other institutional investors have also recently modified their holdings of the company. Advisory Services Network LLC bought a new position in Zoetis during the first quarter valued at approximately $112,000. First Interstate Bank increased its position in Zoetis by 17.5% in the fourth quarter. First Interstate Bank now owns 2,174 shares of the company’s stock valued at $116,000 after buying an additional 324 shares in the last quarter. CENTRAL TRUST Co increased its position in Zoetis by 1.9% in the first quarter. CENTRAL TRUST Co now owns 2,664 shares of the company’s stock valued at $142,000 after buying an additional 49 shares in the last quarter. Huntington National Bank increased its position in Zoetis by 15.7% in the first quarter. Huntington National Bank now owns 2,836 shares of the company’s stock valued at $151,000 after buying an additional 385 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. bought a new position in Zoetis during the third quarter valued at approximately $156,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

Zurcher Kantonalbank Zurich Cantonalbank lowered its position in Zoetis Inc (NYSE:ZTS) by 0.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 97,633 shares of the company’s stock after selling 633 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Zoetis were worth $5,211,000 as of its most recent SEC filing.

Shares of Zoetis Inc (NYSE:ZTS) opened at 62.50 on Monday. Zoetis Inc has a 12 month low of $45.28 and a 12 month high of $63.30. The stock’s 50 day moving average is $58.57 and its 200 day moving average is $54.42. The firm has a market cap of $30.67 billion, a P/E ratio of 36.34 and a beta of 1.07.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 4th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.05. The business had revenue of $1.23 billion during the quarter, compared to analyst estimates of $1.20 billion. Zoetis had a return on equity of 72.96% and a net margin of 14.10%. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period last year, the company earned $0.48 EPS. Equities research analysts expect that Zoetis Inc will post $2.34 EPS for the current year. The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Thursday, June 15th will be paid a $0.105 dividend. This represents a $0.42 annualized dividend and a dividend yield of 0.67%. The ex-dividend date is Tuesday, June 13th. Zoetis’s payout ratio is 30.44%.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 4th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.05. The business had revenue of $1.23 billion during the quarter, compared to analyst estimates of $1.20 billion. Zoetis had a return on equity of 72.96% and a net margin of 14.10%. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period last year, the company earned $0.48 EPS. Equities research analysts expect that Zoetis Inc will post $2.34 EPS for the current year. Several equities research analysts recently weighed in on ZTS shares. BMO Capital Markets reaffirmed a “buy” rating and set a $60.00 price objective on shares of Zoetis in a research report on Wednesday, February 8th. Credit Suisse Group AG upped their price objective on shares of Zoetis from $61.00 to $67.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 24th. Zacks Investment Research raised shares of Zoetis from a “sell” rating to a “hold” rating in a research report on Thursday, March 9th. Guggenheim increased their target price on shares of Zoetis from $60.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, February 16th. Finally, CL King assumed coverage on shares of Zoetis in a report on Friday, May 26th. They issued a “buy” rating and a $71.00 target price for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $60.29.

In related news, insider Catherine A. Knupp sold 5,785 shares of the firm’s stock in a transaction that occurred on Friday, May 12th. The stock was sold at an average price of $60.16, for a total transaction of $348,025.60. Following the completion of the sale, the insider now directly owns 24,415 shares of the company’s stock, valued at approximately $1,468,806.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.05% of the stock is owned by company insiders. Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “ZTS”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment